{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T18:31:01Z","timestamp":1717525861201},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T00:00:00Z","timestamp":1347235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-8722-5-53","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T17:02:07Z","timestamp":1347296527000},"source":"Crossref","is-referenced-by-count":9,"title":["Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study"],"prefix":"10.1186","volume":"5","author":[{"given":"Sara","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Messa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe A","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Levis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,10]]},"reference":[{"key":"246_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cbi.2011.06.007","volume":"193","author":"SY Ho","year":"2011","unstructured":"Ho SY, Wu WJ, Chiu HW, Chen YA, Ho YS, Guo HR, Wang YJ: Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. Chem Biol Interact. 2011, 193: 162-167. 10.1016\/j.cbi.2011.06.007.","journal-title":"Chem Biol Interact"},{"key":"246_CR2","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","volume":"24","author":"GJ Schiller","year":"2006","unstructured":"Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006, 24: 2456-2464. 10.1200\/JCO.2005.03.7903.","journal-title":"J Clin Oncol"},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","volume":"24","author":"N Vey","year":"2006","unstructured":"Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P: Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006, 24: 2465-2471. 10.1200\/JCO.2005.03.9503.","journal-title":"J Clin Oncol"},{"key":"246_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.leukres.2007.05.025","volume":"32","author":"WL Zheng","year":"2008","unstructured":"Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF: Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leuk Res. 2008, 32: 251-254. 10.1016\/j.leukres.2007.05.025.","journal-title":"Leuk Res"},{"key":"246_CR5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V95.3.1014.003k04_1014_1022","volume":"95","author":"C Perkins","year":"2000","unstructured":"Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000, 95: 1014-1022.","journal-title":"Blood"},{"key":"246_CR6","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1038\/sj.onc.1208868","volume":"24","author":"C Scholz","year":"2005","unstructured":"Scholz C, Richter A, Lehmann M, Schulze-Osthoff K, Dorken B, Daniel PT: Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene. 2005, 24: 7031-7042. 10.1038\/sj.onc.1208868.","journal-title":"Oncogene"},{"key":"246_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1182\/blood-2002-04-1154","volume":"102","author":"S Mathas","year":"2003","unstructured":"Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B: Inhibition of NF-kappa B essentially contributes to arsenic-induced apoptosis. Blood. 2003, 102: 1028-1034. 10.1182\/blood-2002-04-1154.","journal-title":"Blood"},{"key":"246_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1756-8722-3-28","volume":"23","author":"C Yedjou","year":"2010","unstructured":"Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 2010, 23: 28-","journal-title":"J Hematol Oncol"},{"key":"246_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/BF02787360","volume":"16","author":"XJ Huang","year":"1999","unstructured":"Huang XJ, Wiernik PH, Klein RS, Gallagher RE: Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol. 1999, 16: 58-64. 10.1007\/BF02787360.","journal-title":"Med Oncol"},{"key":"246_CR10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood.V96.4.1525","volume":"96","author":"GJ Roboz","year":"2000","unstructured":"Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Rafii S: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000, 96: 1525-1530.","journal-title":"Blood"},{"key":"246_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cancergencyto.2010.02.010","volume":"199","author":"M Canestraro","year":"2010","unstructured":"Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N, Metelli MR, Petrini M: Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010, 199: 110-120. 10.1016\/j.cancergencyto.2010.02.010.","journal-title":"Cancer Genet Cytogenet"},{"key":"246_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.2009.08063.x","volume":"149","author":"S Galimberti","year":"2010","unstructured":"Galimberti S, Ghio F, Guerrini F, Ciabatti E, Grassi S, Ferreri MI, Petrini M: WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol. 2010, 149: 451-454. 10.1111\/j.1365-2141.2009.08063.x.","journal-title":"Br J Haematol"},{"key":"246_CR13","doi-asserted-by":"publisher","first-page":"11360","DOI":"10.1158\/0008-5472.CAN-06-1774","volume":"66","author":"D Shackelford","year":"2006","unstructured":"Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R: Targeted degradation of the AML1\/MDS1\/EVI1 oncoprotein by arsenic trioxide. Cancer Res. 2006, 66: 11360-11369. 10.1158\/0008-5472.CAN-06-1774.","journal-title":"Cancer Res"},{"key":"246_CR14","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007, 25: 3503-3510. 10.1200\/JCO.2006.08.5696.","journal-title":"J Clin Oncol"},{"key":"246_CR15","first-page":"358","volume":"83","author":"GF Sanz","year":"1998","unstructured":"Sanz GF, Sanz MA, Greenberg PL: Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998, 83: 358-368.","journal-title":"Haematologica"},{"key":"246_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006, 108: 419-425. 10.1182\/blood-2005-10-4149.","journal-title":"Blood"},{"key":"246_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1038\/sj.leu.2401959","volume":"14","author":"D Boudard","year":"2000","unstructured":"Boudard D, Sordet O, Vasselon C, Revol V, Berth\u00e9as MF, Freyssenet D, Viallet A, Piselli S, Guyotat D, Campos L: Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia. 2000, 14: 2045-2051. 10.1038\/sj.leu.2401959.","journal-title":"Leukemia"},{"key":"246_CR18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1080\/10428190802322919","volume":"49","author":"T Navas","year":"2008","unstructured":"Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, Kambhampati S: Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008, 49: 1963-1975. 10.1080\/10428190802322919.","journal-title":"Leuk Lymphoma"},{"key":"246_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0092-8674(90)90816-W","volume":"61","author":"TJ Schall","year":"1990","unstructured":"Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H: Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell. 1990, 61: 361-370. 10.1016\/0092-8674(90)90816-W.","journal-title":"Cell"},{"key":"246_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2217\/fon.09.175","volume":"6","author":"F Nolte","year":"2010","unstructured":"Nolte F, Hofmann WK: Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010, 6: 445-455. 10.2217\/fon.09.175.","journal-title":"Future Oncol"},{"key":"246_CR21","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009, 113: 6541-6548. 10.1182\/blood-2009-02-202598.","journal-title":"Blood"},{"key":"246_CR22","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68: 3421-3428. 10.1158\/0008-5472.CAN-07-5836.","journal-title":"Cancer Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-5-53\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:05:38Z","timestamp":1594641938000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-5-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,10]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-5-53","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,10]]},"article-number":"53"}}